Editing Oncolytics Biotech Inc.
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
Latest revision | Your text | ||
Line 29: | Line 29: | ||
== Summary == | == Summary == | ||
Oncolytics Biotech is a Canadian development-stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for cancer treatment, specifically with the aim of weakening | Oncolytics Biotech is a Canadian development-stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for cancer treatment, specifically with the aim | ||
of weakening tumour defence mechanisms. Oncolytics Biotech aims to use immunotherapeutics - a branch of biological therapies that use synthetic substances to activate the immune system for stronger responses. This approach proposes many new treatments that will support the immune system in a more powerful fight against cancer. The company's lead product is Pelareorep, simply put, Pelareorep is an oncolytic virus that causes tumour cells to burst and activates multiple immune system entities. | |||
Oncolytics Biotech has also decided to embark on a co-developmental journey with Merck KGaA and Pfizer to combine Pelareorep with Paclitaxel, a chemotherapy medication, and Avelumab, an anti-cancer antibody medication. This combination is being tested because oncolytic viruses, such as Pelareorep, have the potential to enhance existing cancer treatments like Paclitaxel and Avelumab, leading to the elimination of resistant cancer cells and reducing cancer relapses. Oncolytics Biotech is conducting experiments on breast cancer cells using Pelareorep and Pfizer's drug Bavencio (Avelumab). | Oncolytics Biotech has also decided to embark on a co-developmental journey with Merck KGaA and Pfizer to combine Pelareorep with Paclitaxel, a chemotherapy medication, and Avelumab, an anti-cancer antibody medication. This combination is being tested because oncolytic viruses, such as Pelareorep, have the potential to enhance existing cancer treatments like Paclitaxel and Avelumab, leading to the elimination of resistant cancer cells and reducing cancer relapses. Oncolytics Biotech is conducting experiments on breast cancer cells using Pelareorep and Pfizer's drug Bavencio (Avelumab). |